Group 1 - The stock price of Chengda Pharmaceutical closed at 27.34 yuan on August 14, 2025, down by 1.59 yuan, representing a decline of 5.50% from the previous trading day [1] - The trading volume on that day was 98,100 hands, with a transaction amount of 276 million yuan, and a turnover rate of 9.04% [1] - Chengda Pharmaceutical's main business includes pharmaceutical research and development, production, and involves areas such as CRO and biopharmaceuticals [1] Group 2 - The company is progressing with its innovative biocell drug project, although specific advancements or clinical trial arrangements have not been disclosed [1] - On August 14, there was a net outflow of 18.51 million yuan in main funds, with a cumulative net outflow of 14.57 million yuan over the past five days [1]

诚达药业首次公开发行股票的发行费用总额为13,576.31万元，其中，保荐承销费用11,792.90万元。 2023年7月3日，诚达药业发布2022年度权益分派实施公告。公司2022年年度权益分派方案为：以公司现 有总股本96,696,140股为基数，向全体股东每10股派3.000000元人民币现金，同时，以资本公积金向全 体股东每10股转增6.000000股。本次权益分派股权登记日为2023年7月6日，除权除息日为2023年7月7 日。 诚达药业首次公开发行股票募集资金总额为175,721.06万元，扣除发行费用后募集资金净额162,144.75万 元。诚达药业实际募资净额比原拟募集资金多110,816.71万元。诚达药业于2022年1月14日披露的招股说 明书显示，该公司原拟募集资金51,328.04万元，分别用于"医药中间体项目、原料药项目及研发中心扩 建项目"和"补充流动资金"。 中国经济网北京8月14日讯诚达药业（301201）(301201.SZ)今日股价下跌，截至收盘报27.34元，跌幅 5.50%，该股目前处于破发状态。 诚达药业于2022年1月20日在深交所创业板上市，公开发行新股2,417 ...

Market Overview - On August 14, the medical services sector declined by 0.47%, with XD Zhaoyan leading the drop [1] - The Shanghai Composite Index closed at 3666.44, down 0.46%, while the Shenzhen Component Index closed at 11451.43, down 0.87% [1] Top Gainers in Medical Services - Nanjing Momo Biological Technology (688265) saw a closing price of 60.60, up 16.20% with a trading volume of 45,800 shares and a transaction value of 262 million [1] - Innovation Medical (002173) closed at 24.92, up 10.02% with a trading volume of 1,071,000 shares and a transaction value of 2.609 billion [1] - Sanbo Brain Science (301293) closed at 67.82, up 8.51% with a trading volume of 396,800 shares and a transaction value of 2.618 billion [1] Top Losers in Medical Services - XD Zhaoyan (603127) closed at 32.21, down 5.74% with a trading volume of 455,800 shares and a transaction value of 1.497 billion [2] - Chengda Pharmaceutical (301201) closed at 27.34, down 5.50% with a trading volume of 98,100 shares and a transaction value of 276 million [2] - ST Biological (000504) closed at 10.75, down 5.04% with a trading volume of 110,000 shares and a transaction value of 120 million [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 364 million from institutional investors, while retail investors saw a net inflow of 138 million [2] - Notable net inflows from retail investors were observed in Innovation Medical (002173) with 117 million, while significant outflows were noted in Sanbo Brain Science (301293) with 46 million [3]

证券之星消息，8月11日医疗服务板块较上一交易日上涨1.71%，海特生物领涨。当日上证指数报收于 3647.55，上涨0.34%。深证成指报收于11291.43，上涨1.46%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300683 | 海特生物 | 55.27 | 8.67% | 13.17万 | | 7.08亿 | | 688621 | 阳光诺和 | 68.66 | 8.47% | 8.82万 | | · 5.81亿 | | 301201 | 诚达药业 | 29.56 | 7.57% | 10.19万 | | 2.94亿 | | 002173 | 创新医疗 | 18.72 | 6.36% | 147.62万 | | 27.39亿 | | 000504 | *ST生物 | 12.54 | 5.03% | 8.56万 | | 1.07亿 | | 300149 | 睿智医药 | 12.94 | 4.19% | 49.79万 | | 6.37亿 | ...

证券之星消息，8月4日医疗服务板块较上一交易日下跌0.26%，昭衍新药领跌。当日上证指数报收于 3583.31，上涨0.66%。深证成指报收于11041.56，上涨0.46%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | | 成交额(元) | | --- | --- | --- | --- | --- | --- | --- | | 688265 | 南模生物 | 43.73 | 20.01% | | 4.08万 | 1.66亿 | | 688621 | 阳光诺和 | 66.54 | 14.84% | | 12.60万 | 8.15亿 | | 301201 | 诚达药业 | 28.10 | 4.04% | | 10.58万 | 2.93亿 | | 688222 | 成都先导 | 24.74 | 3.82% | | 33.55万 | 7.91亿 | | 002172 | 澳洋健康 | 4.25 | 3.41% | | 70.07万 | 2.93亿 | | 688046 | 药康生物 | 16.41 | 3.01% | | 4.55万 | 7293.23万 | | ...

7月23日，截至收盘，医疗服务行业上涨1.3%，板块资金流入6.19亿。上涨个股家数31个，下跌个股家 数13个。 板块跌幅居前的股票包括：诚达药业（-13.12%）、成都先导（-2.8%）、华康洁净（-2.62%）、创新医 疗（-2.13%）、百诚医药（-1.74%）、大东方（-1.39%）、三博脑科（-0.66%）、健麾信息 （-0.54%）、澳洋健康（-0.5%）、皓宸医疗（-0.33%）、博济医药（-0.29%）、一致Ｂ（-0.23%）、 美年健康（-0.2%） 来源：金融界 板块跌幅居前的十大熊股分别是：诚达药业（-13.12%）、成都先导（-2.8%）、华康洁净（-2.62%）、 创新医疗（-2.13%）、百诚医药（-1.74%）、大东方（-1.39%）、三博脑科（-0.66%）、健麾信息 （-0.54%）、澳洋健康（-0.5%）、皓宸医疗（-0.33%）、博济医药（-0.29%）、一致Ｂ（-0.23%）、 美年健康（-0.2%）、盈康生命（0.2%）、诺禾致源（0.26%）、何氏眼科（0.3%）、睿智医药 （0.36%）、新里程（0.45%）、光正眼科（0.64%）、泰格医药（0.66%） 序代 ...

Group 1 - The stock price of Chengda Pharmaceutical (301201.SZ) fell by 13.12% to 27.62 yuan as of the close on July 23, 2023 [1] - Chengda Pharmaceutical was listed on the Shenzhen Stock Exchange's ChiNext board on January 20, 2022, with an initial public offering (IPO) of 24,174,035 shares at a price of 72.69 yuan per share [1] - The highest stock price recorded on the first day of trading was 188.00 yuan, indicating a significant decline since then, as the stock is currently in a state of "breaking" [1] Group 2 - The total amount raised from the IPO was 1,757.21 million yuan, with a net amount of 1,621.45 million yuan after deducting issuance costs [1] - The actual net fundraising exceeded the original planned amount by 1,108.17 million yuan, which was initially set at 513.28 million yuan for various projects and working capital [1] - The total issuance costs for the IPO were 135.76 million yuan, with underwriting fees amounting to 117.93 million yuan [1] Group 3 - On July 3, 2023, Chengda Pharmaceutical announced its 2022 annual equity distribution plan, which includes a cash dividend of 3.00 yuan for every 10 shares and a capital reserve conversion of 6 additional shares for every 10 shares held [2] - The record date for the equity distribution was set for July 6, 2023, and the ex-dividend date was July 7, 2023 [2]

Group 1 - The innovative drug sector is experiencing a resurgence, with significant stock price increases for companies such as Chengda Pharmaceutical (+14.05%) and Huisheng Pharmaceutical (+9.45%) [1][2] - The National Healthcare Security Administration (NHSA) is actively promoting high-quality development of innovative drugs through a series of meetings and discussions with industry representatives [3] - The NHSA's commitment to supporting genuine innovation and establishing a comprehensive value evaluation system for innovative drugs is expected to enhance the efficient use of healthcare resources [3] Group 2 - CITIC Securities reports that the NHSA's ongoing efforts in centralized procurement and negotiation will shift the market focus from low-price competition to quality and cost control, benefiting companies with strong quality systems and cost advantages [4] - The innovative drug sector is anticipated to receive continued policy support, with commercial insurance policies providing additional growth opportunities [4] - By 2025, the domestic innovative drug industry is expected to reach a turning point, transitioning from capital-driven to profit-driven growth, presenting dual opportunities for performance and valuation recovery [4]

创新药概念股反复活跃 成都先导、诚达药业双双涨超10% 智通财经7月22日电，成都先导、诚达药业双双涨超10%，百奥泰、赛升药业、丽珠集团、海特生物、 辰欣药业、健康元等多股涨超5%。消息面上，国家医保局召开医保支持创新药械系列座谈会第一场， 围绕"对创新药械开展医保综合价值评价"议题深入交流，提出意见建议。 ...

Group 1 - The CRO concept sector experienced a short-term surge, with Chengda Pharmaceutical (301201) rising over 10% [1] - Other companies such as Xuantai Pharmaceutical, Medisi, Saintno Biological, Sichuan Shuangma (000935), and Dezhan Health (000813) also saw increases [1] - There is a notable flow of "smart money" into the market, indicating a strategic investment trend [1]